Impact of Optimal Pharmacotherapy on Lipid Profile and Qualitative Features of Atherosclerotic Plaques
NCT ID: NCT05639218
Last Updated: 2023-11-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
50 participants
OBSERVATIONAL
2021-06-29
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Aim of this study is to evaluate the effect of optimal hypolipidemic pharmacotherapy, including PCSK9 inhibitors and inclisiran, on plasma lipid profile and qualitative features of atherosclerotic plaques in very-high cardiovascular risk patients.
This study enrolls patients with an established atherosclerotic cardiovascular disease, receiving PCSK9 inhibitors or inclisiran as add-on treatment to statins in maximally tolerated dose and/or ezetimibe.
Effect of hypolipidemic pharmacotherapy is evaluated by analysis of plasma lipid profile parameter changes and qualitative features of atherosclerotic plaques using Near-Infrared Spectroscopy Intravascular Ultrasound Imaging (NIRS-IVUS) method.
Results of the study would be sufficient for complementing evidence regarding therapeutic strategy in very-high cardiovascular risk patients.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Lipid accumulation in artery walls is the pathogenetic cornerstone of atherosclerosis. The most commonly studied risk factor of atherosclerotic cardiovascular disease is low-density lipoprotein cholesterol (LDL-C), nevertheless other plasma lipids have an established role as well. LDL-C is considered the primary target for cardiovascular risk reduction, with therapeutic goal \<1.4 mmol/l in very-high cardiovascular risk patients with established atherosclerotic cardiovascular disease. Standard hypolipidemic therapy, based on statins and ezetimibe, is not always effective enough. Novel and promising direction is proprotein convertase subtilisin/kexin type 9 (PCSK9) - protease that binds LDL receptors in hepatocytes, subsequently promoting their lysosomal degradation. This process leads to reduced intracellular LDL-C uptake and increased LDL-C concentration in plasma. PCSK9 inhibitors - monoclonal antibodies evolocumab and alirocumab are successfully used in clinical practice, with a proven effectiveness in clinical trials ODYSSEY and FOURIER. An innovative medication is inclisiran - small interfering ribonucleic acid (siRNA) molecule that interferes with translation of messenger RNA (mRNA) of PCSK9 in hepatocytes as a result of complementary binding. Subsequently levels of synthesized PCSK9 are reduced, resulting in positive impact on plasma lipid profile. Inclisiran has demonstrated remarkable efficacy and safety profile in ORION clinical trials, being registered in European Medicines Agency since year 2020. Real-world data regarding optimal lipid-lowering pharmacotherapy, including experience with new medications, is of great clinical interest, studying effect on plasma lipid profile, as well as qualitative features of atherosclerotic plaques using Near-Infrared Spectroscopy Intravascular Ultrasound Imaging (NIRS-IVUS) method.
Aim:
Aim of this study is to evaluate effect of optimal hypolipidemic pharmacotherapy on plasma lipid profile and and qualitative features of atherosclerotic plaques in very-high cardiovascular risk patients receiving PCSK9 inhibitors or inclisiran as add-on treatment to statins in maximally tolerated dose and/or ezetimibe.
Study design:
Prospective observational study.
Study population:
Very-high cardiovascular risk patients with an established atherosclerotic cardiovascular disease, receiving PCSK9 inhibitors or inclisiran as add-on treatment to statins in maximally tolerated dose and/or ezetimibe in the context of optimal hypolipidemic pharmacotherapy, in whom NIRS-IVUS investigation has been performed.
Data acquisition:
Patients fulfilling eligibility criteria and agreeing to participate in the study are included. Baseline demographic and medical data is acquired, with subsequent follow-up ambulatory visits after 3 and 6 months after PCSK9 inhibitor or inclisiran therapy initiation. After 15 months since inclusion, follow-up with NIRS-IVUS performed is foreseen. For analysis of obtained data MS Excel and IBM SPSS Statistics software is used.
Clinical implications:
Results of this study would be of high clinical interest for complementing evidence and improving outcomes regarding therapeutic strategy in very-high cardiovascular risk patients with an established atherosclerotic cardiovascular disease.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Inclisiran
Patients are receiving PCSK9 inhibitors or inclisiran in the context of optimal hypolipidemic pharmacotherapy
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* On maximally tolerated statin and/or ezetimibe therapy for at least 1 month LDL-C treatment target \<1.4 mmol/l not achieved
* Receiving PCSK9 inhibitor or inclisiran as add-on treatment to maximally tolerated statin dose and/or ezetimibe in the context of optimal pharmacotherapy
* NIRS-IVUS performed (written informed consent for the procedure signed according to regulations in the hospital)
* Available blood test results - plasma lipid profile
* Patient agrees to participate in the study (signed informed consent)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pauls Stradins Clinical University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Karlis Trusinskis
MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Karlis Trusinskis, MD
Role: PRINCIPAL_INVESTIGATOR
Pauls Stradins Clinical University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pauls Stradins Clinical University Hospital
Riga, , Latvia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PCSK9I-0621
Identifier Type: -
Identifier Source: org_study_id